Seattle Genetics

Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020

Retrieved on: 
Sunday, December 6, 2020
Medical specialties, Medicine, Health, Cancer immunotherapy, CD47, Antibody, Oncology, Tumors of the hematopoietic and lymphoid tissues, Takeda Pharmaceutical Company, Sutro Biopharma, Seattle Genetics

BRISBANE, Calif. and ST. LOUIS, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the ASH Annual Meeting 2020.

Key Points: 
  • BRISBANE, Calif. and ST. LOUIS, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the ASH Annual Meeting 2020.
  • At ASH this year, we are pleased to highlight the growing body of preclinical data on AO-176, demonstrating a breadth of efficacy data in models of lymphoma, AML, and multiple myeloma, said Daniel Pereira, Ph.D., Chief Scientific Officer of Arch Oncology.
  • Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies.
  • In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer.

Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

Retrieved on: 
Wednesday, October 14, 2020
Companies, Life sciences, Industries, Genentech, Hoffmann-La Roche, South San Francisco, California, RTT, Cancer immunotherapy, Oncology, Acute myeloid leukemia, Seattle Genetics

Details of the poster session are as follows:

Key Points: 
  • Details of the poster session are as follows:
    Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
  • In 2015, Curis entered into a collaborationwith Aurigene in the areas of immuno-oncology and precision oncology.
  • CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes.
  • Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge for the treatment of advanced basal cell carcinoma.

Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.

Retrieved on: 
Thursday, October 8, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Clinical medicine, Medicine, Biotechnology, Antineoplastic drugs, Immunology, Antibody-drug conjugate, Seattle Genetics, SeaGen, Seattle, Health care

The change in our corporate name from Seattle Genetics to Seagen reflects who we are today, as we expand our presence beyond the Pacific Northwest and outside of the United States to support the commercialization of TUKYSA globally, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen.

Key Points: 
  • The change in our corporate name from Seattle Genetics to Seagen reflects who we are today, as we expand our presence beyond the Pacific Northwest and outside of the United States to support the commercialization of TUKYSA globally, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen.
  • As a pioneer in antibody-drug conjugates (ADCs), Seagen has been a leader in novel cancer therapeutics for more than 20 years.
  • Along with the new name, the company will adopt a new logo and will change its corporate website from www.seattlegenetics.com to www.seagen.com .
  • Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Retrieved on: 
Monday, September 21, 2020
Health, Cancer treatments, Seattle Genetics, Breakthrough therapy, Monoclonal antibodies, Genmab, Antibody-drug conjugates, Monomethyl auristatin E, European Society for Medical Oncology, Clinical endpoint, Glembatumumab vedotin, Brentuximab vedotin

Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • Tisotumab vedotin has demonstrated meaningful clinical activity in patients with recurrent and/or metastatic cervical cancer for whom there is a high unmet need for new therapies, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.
  • Data presented at ESMO include the primary endpoint of confirmed ORR as assessed by independent central review in 101 patients treated with tisotumab vedotin in the trial.
  • For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.

Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Retrieved on: 
Monday, September 21, 2020
Research, FDA, Public relations, Investor relations, Clinical trials, Communications, General Health, Pharmaceutical, Health, Science, Oncology, Seattle Genetics, Drugs, Health care, Pharmaceutical companies, Genmab, European Society for Medical Oncology, Breakthrough therapy, Monoclonal antibodies, Antibody-drug conjugates, Orphan drugs, Glembatumumab vedotin, Enfortumab vedotin, Cervical Cancer, the innovaTV 204 Trial, Tisotumab Vedotin, Seattle Genetics, Genmab

Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • We are encouraged by the innovaTV 204 trial results, which suggests that tisotumab vedotin as a monotherapy could potentially become an important option for women with metastatic and or recurrent cervical cancer, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
  • Data presented at ESMO include the primary endpoint of confirmed ORR as assessed by independent central review in 101 patients treated with tisotumab vedotin in the trial.
  • For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.

Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Retrieved on: 
Friday, September 18, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Clinical medicine, Health, Medicine, Breakthrough therapy, Monoclonal antibodies, Cancer treatments, Cancer immunotherapy, Orphan drugs, Enfortumab vedotin, Clinical endpoint, Transitional cell carcinoma, Chemotherapy, the EV-301 Trial, PADCEV® (enfortumab vedotin-ejfv), Seattle Genetics, Astellas, the Seattle Genetics and Astellas Collaboration

The global EV-301 clinical trial compared PADCEV to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.

Key Points: 
  • The global EV-301 clinical trial compared PADCEV to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.
  • We continue to explore PADCEVs activity across the spectrum of urothelial cancer including its potential for use in earlier lines of therapy.
  • The primary endpoint is overall survival of participants treated with PADCEV compared to those treated with chemotherapy.
  • Secondary endpoints include progression-free survival, duration of response, and overall response rate, as well as assessment of safety/tolerability and quality-of-life parameters.

Global Non-Hodgkin Lymphoma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 15, 2020
Health, Oncology, RTT, Cancer, Clinical medicine, Medicine, Lymphoma, Non-Hodgkin lymphoma, Hodgkin lymphoma, Hodgkin, Seattle Genetics

The "Global Non-Hodgkin Lymphoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Hodgkin Lymphoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Non-Hodgkin Lymphoma Market and Competitive Landscape - 2020, provides comprehensive insights into the Non-Hodgkin Lymphoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Non-Hodgkin Lymphoma market size and drug sales.
  • Non-Hodgkin Lymphoma pipeline: Find out drugs in clinical trials for the treatment of Non-Hodgkin Lymphoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Non-Hodgkin Lymphoma drugs: Identify key drugs marketed and prescribed for Non-Hodgkin Lymphoma in the US, including trade name, molecule name, and company
    Non-Hodgkin Lymphoma market valuations: Find out the market size for Non-Hodgkin Lymphoma drugs in 2019 by countries.

Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

Retrieved on: 
Monday, September 14, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Seattle Genetics, Merck, MRK, Seattle, Puget Sound region, Health care, Companies, Ladiratuzumab Vedotin, TUKYSA (tucatinib), KEYTRUDA® (pembrolizumab) Injection, 100 mg, Seattle Genetics, Merck

Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.
  • Seattle Genetics will receive $125 million from Merck as an upfront payment and is eligible for progress-dependent milestones of up to $65 million.
  • Merck will pay Seattle Genetics $600 million upfront and make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share.
  • Seattle Genetics will receive from Merck $125 million as an upfront payment and is eligible to receive progress-dependent milestones of up to $65 million.

Global Hodgkin Lymphoma Market (2020 to 2024) - Track Key Events and Trends - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 10, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer, RTT, Clinical medicine, Medicine, Infectious causes of cancer, Hodgkin lymphoma, Lymphoma, Seattle Genetics, Entospletinib

The "Global Hodgkin Lymphoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hodgkin Lymphoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Hodgkin Lymphoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Hodgkin Lymphoma treatment options, Hodgkin Lymphoma late stage clinical trials pipeline, Hodgkin Lymphoma prevalence by countries, Hodgkin Lymphoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Hodgkin Lymphoma pipeline: Find out drugs in clinical trials for the treatment of Hodgkin Lymphoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Hodgkin Lymphoma drugs: Identify key drugs marketed and prescribed for Hodgkin Lymphoma in the US, including trade name, molecule name, and company
    Hodgkin Lymphoma market valuations: Find out the market size for Hodgkin Lymphoma drugs in 2019 by countries.

Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Retrieved on: 
Thursday, September 3, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Seattle Genetics, Seattle, NASDAQ, Puget Sound region, Finance, Economy of the United States

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 3:30 p.m. Eastern Time.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 3:30 p.m. Eastern Time.
  • The presentation will be webcast live and available for replay from Seattle Genetics website at www.seattlegenetics.com in the Investors section.
  • Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives.
  • The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union.